Search the Newsreel

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Maplight Therapeutics (NASDAQ:MPLT) from "strong sell" to "sell," though the stock still holds a consensus "Moderate Buy" rating with an average price target of $29.67. The company recently reported better-than-expected quarterly EPS of -$1.32, and an insider director purchased 15,620 …

Maplebear Inc. Stock 12‑Month Price Target Raised to $58.15, Implies 19% Upside

Analysts have raised the average 12-month price target for Maplebear Inc. stock to $58.15, up from $57.85. This new target suggests a potential upside of approximately 19% from the August 14 closing price. The consensus rating among 34 analysts remains a "Buy," with 18 …

Stoneweg Europe Stapled Trust (SGX:SET) Stock Yield Faces Cash Coverage Strain

MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside

The average 12-month price target for MapLight Therapeutics, Inc. (MPLT) stock has been revised down slightly to $28.77 from $29.31, based on estimates from 13 analysts. This new target suggests a significant 148% potential upside from its Aug. 13 closing price. The consensus rating …

Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com

Investing.com reports on a Form 8K filing by MapLight Therapeutics Inc. for August 13th. The article mentions the company's stock symbol MPLT and its daily performance, showing a 1.47% increase.

Associate Global Partners slips again as thinly traded fund manager tests investors' patience

MapLight Therapeutics stock jumps on $150M private placement

MapLight Therapeutics Inc (NASDAQ:MPLT) shares increased by 5.2% following the announcement of a $150 million private placement financing. The company plans to use the proceeds to advance ML-007C-MA, supporting its VISTA Phase 2 study in Alzheimer’s disease psychosis and the ZEPHYR-2 registrational Phase 3 …

Maple Leaf Foods (TSX:MFI) Stock Drifts Despite Resilient Margins And Steady Outlook

Maplebear (CART) insider plans 25,000-share Rule 144 stock sale on NASDAQ

An insider at Maplebear, Inc. (CART) has filed a Rule 144 notice to sell up to 25,000 shares of common stock through Charles Schwab & Co., Inc. on NASDAQ. The aggregate market value of these shares is $1,250,223.00. This sale is related to underlying …

MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary

MapLight Therapeutics (MPLT) reported a net loss of $60.2 million and a loss per share of $(1.32) for the second quarter of 2026, remaining pre-revenue. The increased loss compared to Q2 2025 was due to a significant ramp in clinical trial activity and operational …

MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal

Could Maple Leaf Foods (TSX:MFI) Surprise Markets Again?

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …

Maple Leaf Foods (TSE:MFI) Given New C$37.00 Price Target at Ventum Financial

Maple Leaf Foods (TSE:MFI) Given New C$33.00 Price Target at Scotiabank

National Bank Financial Issues Pessimistic Forecast for Maple Leaf Foods (TSE:MFI) Stock Price

Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4% - Here's Why

Maplight Therapeutics (NASDAQ:MPLT) saw its stock rise by 6.4% in midday trading on Thursday, despite significantly lower trading volume. The company holds a "Moderate Buy" consensus from analysts with an average price target of $31.17, although it recently reported an earnings per share miss. …

MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics has announced a $150 million private placement financing, selling common stock and pre-funded warrants to institutional and accredited investors. The proceeds will primarily fund the advancement of ML-007C-MA for Alzheimer's disease psychosis and schizophrenia, including ongoing Phase 2 and planned Phase 3 …

Maple Leaf Foods Stock Faces Fresh Pressure After August 12 Decline as Earnings and Margin Risks Test Investor Confidence

Stoneweg Europe Stapled Trust, Sponsor Explore Structural Changes to Boost Long-Term Value

Maplight Therapeutics (MPLT) Earnings Date and Reports 2026

APL Apollo Tubes Shares Rise 2.26% to Rs 2,042.20; Net Profit Surges in FY26

Stoneweg Europe Stapled Trust evaluates management internalisation, posts 1.4% rise in H1 DPS to 0.06642 euro

Stoneweg Europe Stapled Trust's H1 Distributable Income Flat at EUR37 Million

Maple Leaf Foods Inc (MLFNF) (Q2 2026) Earnings Call Highlights: Margin Expansion and Strategic ...

This article first appeared on GuruFocus. Revenue: $1.02 billion in Q2 2026, an increase of 1.6% year-over-year. Adjusted EBITDA: $137.1 million, up 4.8% from the prior year quarter. Adjusted EBITDA Margin: Expanded by 40 basis points to 13.4%. Prepared Foods Sales: Decreased 2% due …

Maplebear CEO Chris Rogers Sells 4,933 Shares at $50

Maplebear CEO Chris Rogers sold 4,933 shares of the company (Instacart) at $50.00 per share on August 7, 2026, totaling $246,650. This transaction was executed under a Rule 10b5-1 trading plan and represents a minor reduction (0.51%) in his direct holdings. Following the sale, …

Maplebear Inc. (CART) large Sequoia holder makes 6.1M-share in-kind distribution

Entities associated with Sequoia Capital, major shareholders of Maplebear Inc. (CART), have reported an internal restructuring involving a pro rata in-kind distribution of 6,127,968 shares of Maplebear common stock to their partners or members. This transaction, made for no consideration, resulted in adjusted indirect …

Sequoia entities keep 9.5% Maplebear Inc. (CART) stake after in-kind share distribution

Sequoia Capital-affiliated entities have reported an updated beneficial ownership of 9.5% in Maplebear Inc. (CART) following a pro rata in-kind distribution of shares to their partners on August 10, 2026. This distribution involved Sequoia Capital Fund, L.P. (SCF) and Sequoia Capital Fund Parallel, LLC …

Can Maplebear's AI Assistant Become a Meaningful Growth Driver?

Maplebear Inc. (Instacart) is heavily investing in its new AI Assistant to boost platform growth and user engagement, with early results showing larger basket sizes. The AI Assistant synthesizes user preferences, order history, inventory, and promotions to create complete shopping carts and is also …

Stoneweg Europe Stapled Trust refreshes board to bolster governance and succession

CAPLIPOINT: Strong revenue growth, margin expansion, and strategic investments drive future outlook

China Maple Leaf Educational Systems Updates Board and Committee Structure